rofecoxib nonsteroidal antiinflammatory drug nsaid marketed merck co treat osteoarthritis rheumatoid arthritis juvenile rheumatoid arthritis acute pain conditions migraine dysmenorrhea rofecoxib approved us us food drug administration fda may marketed brand names vioxx ceoxx ceeoxx rofecoxib available prescription tablets oral rofecoxib gained widespread use among physicians treating patients arthritis conditions causing chronic acute pain worldwide million people prescribed rofecoxib september merck voluntarily withdrew rofecoxib market concerns increased risk heart attack stroke associated longterm highdosage use merck withdrew drug disclosures withheld information rofecoxibs risks doctors patients five years allegedly resulting cases serious heart rofecoxib one widely used drugs ever withdrawn market year withdrawal merck sales revenue billion fda issued memorandum concluding risks serious cardiovascular cv events seem great nonselective nsaids agents rofecoxib according longterm controlled clinical based data fda reasserted likelihood increased risk serious adverse cv events nonselective nsaids dependent dose november massachusettsbased tremeau pharmaceuticals announced plan return rofecoxib market treatment hemophilic arthropathy ha tremeau announced fda granted orphan designation rofecoxib treatment ha received fda feedback development ha degenerative joint disease caused recurrent intraarticular bleeding largest cause morbidity patients hemophilia currently approved treatment options united states traditional nsaids avoided population due effects platelet aggregation risk gastrointestinal high potency opioids current standard care treating cyclooxygenase cox two wellstudied isoforms called mediates synthesis prostaglandins responsible protection stomach lining mediates synthesis prostaglandins responsible pain inflammation creating selective nsaids inhibit pain relief traditional nsaids offered greatly reduced risk fatal debilitating peptic ulcers rofecoxib selective inhibitor coxib though class coxibs includes several agents degrees selectivity vary among celecoxib celebrex least selective rofecoxib vioxx valdecoxib bextra etoricoxib arcoxia highly time withdrawal rofecoxib coxib approved united states clinical evidence superior gastrointestinal adverse effect profile conventional nsaids largely based vigor vioxx gi outcomes research study compared efficacy adverse effect profiles rofecoxib therapeutic recommended dosages mg approximate bioavailability rofecoxib crossed placenta took hours reach peak plasma concentration effective halflife based steadystate levels around metabolic products cisdihydro transdihydro derivatives primarily excreted urine rofecoxib approved fda treat osteoarthritis rheumatoid arthritis juvenile rheumatoid arthritis acute pain conditions migraine dysmenorrhea marketed gained widespread acceptance among physicians treating patients arthritis conditions causing chronic acute placebocontrolled small shortterm study india women premenstrual acne vulgaris given rofecoxib placebo two cycles days suggest rofecoxib effective management premenstrual march scott reuben former chief acute pain baystate medical center springfield mass revealed data studies authored efficacy drug along others celecoxib fabricated overstating analgesic effects drugs evidence found reuben colluded merck falsifying data reuben also former paid spokesperson drug company pfizer owns intellectual property rights marketing celecoxib united states retracted studies submitted either fda european unions regulatory agencies prior drugs approval drug manufacturer merck comment addition reduced incidence gastric ulceration rofecoxib exhibits effect bleeding time platelet aggregation even supratherapeutic aside features rofecoxib exhibits similar adverseeffect profile nsaids vigor vioxx gi outcomes research study conducted bombardier et al compared efficacy adverseeffect profiles supratherapeutic dose rofecoxib mgday vs common dose naproxen mgbid indicated significant fourfold increased risk acute myocardial infarction heart attack rofecoxib patients compared naproxen patients vs relative risk mean duration months elevated risk began second month rofecoxib significant difference mortality cardiovascular events seen two groups significant difference occur rate myocardial infarction rofecoxib naproxen treatment groups patients without high cardiovascular risk difference overall risk patients higher risk heart attack ie meeting criteria lowdose aspirin prophylaxis secondary cardiovascular events previous myocardial infarction angina cerebrovascular accident transient ischemic attack coronary artery mercks scientists interpreted finding protective effect naproxen telling fda difference heart attacks primarily due protective needed martin report excused senior management stating believed victims pfizers alleged manipulation test results promote product safer commentators noted naproxen would three times effective aspirin account outside scientists warned merck claim implausible vigor evidence since emerged large cardioprotective effect naproxen although number studies found protective effects similar size results vigor study submitted us fda february september fda sent warning letter ceo merck stating promotional campaign discounts fact vigor study patients vioxx observed four fivefold increase myocardial infarctions mis compared patients comparator nonsteroidal antiinflammatory drug nsaid naprosyn led introduction april warnings vioxx labeling concerning increased risk cardiovascular events heart attack stroke months preliminary version vigor published new england journal medicine november journal editors learned certain data reported fda included nejm article several years later shown merck memo depositions first federal vioxx trial realized data available authors months publication editors wrote editorial accusing authors deliberately withholding released editorial media december giving authors chance respond nejm editor gregory curfman explained quick release due imminent presentation deposition testimony feared would misinterpreted media earlier denied relationship timing editorial trial although testimony actually used december trial curfman testified well publication editors charged four months article published least two authors aware critical data array adverse cardiovascular events included vigor article additional data included three additional heart attacks raised relative risk vioxx additional heart attacks occurred group low risk heart attack aspirin indicated group editors noted omission resulted misleading conclusion difference risk myocardial infarction aspirin indicated aspirin indicated groups relative risk myocardial infarctions among aspirin indicated patients increased although remained statistically insignificant editors also noted statistically significant twofold increase risk serious thromboembolic events group outcome merck reported nejm though disclosed information publicly march eight months authors study including nonmerck authors responded claiming three additional heart attacks occurred prespecified cutoff date data collection thus appropriately included using prespecified cutoff date also meant additional stroke naproxen population reported furthermore said additional data qualitatively change conclusions study results full analyses disclosed fda reflected vioxx warning label noted data omitted table printed text article authors stood original nejm stood editorial noting cutoff date never mentioned article authors report cutoff cardiovascular adverse events gastrointestinal adverse events different cutoffs increased reported benefits vioxx reduced stomach problems relative risks increased heart scientists accused nejm editorial board making unfounded others applauded editorial renowned research cardiologist eric prominent merck critic accused merck manipulation data said think scientific misconduct trial really fully backed phil fontanarosa executive editor prestigious journal american medical association welcomed editorial saying another long list recent examples generated real concerns trust confidence industrysponsored may wall street journal reported latenight email written outside public relations specialist sent journal staffers hours expression concern released predicted rebuke would divert attention merck induce media ignore new england journal medicines role aiding vioxx internal emails show new england journals expression concern timed divert attention deposition executive editor gregory curfman made potentially damaging admissions journals handling vioxx study deposition part vioxx litigation dr curfman acknowledged lax editing might helped authors make misleading claims article journal stated nejms ambiguous language misled reporters incorrectly believing merck deleted data regarding three additional heart attacks rather blank table contained statistical information new england journal says didnt attempt mistakes investigations revealed merck several years worth information suggesting elevated risk cardiac events vice president edward scolnick took much blame suppression fda reviewers aware potential cardiovascular risk argued merck manipulated ekg tests one week external review board provided consultation specifically exclude high risk factors trial subjects avoid finding effect predated changes trials almost three months merck conducted several studies rofecoxib aimed determining drug slowed onset alzheimers disease merck placed great emphasis studies grounds relatively large almost patients compared rofecoxib placebo rather another pain reliever studies found elevated death rate among rofecoxib patients although deaths generally heartrelated however find elevated cardiovascular risk due merck cited studies providing evidence contrary vigor rofecoxibs safety merck commenced approve adenomatous polyp prevention vioxx study threeyear trial primary aim evaluating efficacy rofecoxib prophylaxis colorectal polyps celecoxib already approved indication hoped add indications rofecoxib well additional aim study evaluate cardiovascular safety rofecoxibcitation needed approve study terminated early preliminary data study showed increased relative risk adverse thrombotic cardiovascular events including heart attack stroke beginning months rofecoxib therapy patients taking rofecoxib versus placebo relative risk events rofecoxib events vs placebo events per patient years results first months approve study show increased relative risk adverse cardiovascular events moreover overall cardiovascular mortality rates similar rofecoxib placebo summary approve study suggested longterm use rofecoxib resulted nearly twice risk suffering heart attack stroke compared patients receiving placebo preapproval phase iii clinical trials like approve study showed increased relative risk adverse cardiovascular events first months rofecoxib usage merck others pointed study preapproval trial showed threefold increase cardiovascular events compared placebo sevenfold increase compared nabumetone another nsaid eightfold increase heart attacks strokes combined compared control although relatively small study last result statistically significant critics charged early finding prompted merck quickly conduct larger studies rofecoxibs cardiovascular safety merck notes already begun vigor time study completed although vigor primarily designed demonstrate new uses rofecoxib also collected data adverse cardiovascular outcomes several large observational studies also found elevated risk heart attack rofecoxib example recent retrospective study elderly canadians suggested borderline statistically significant increased relative risk heart attacks vioxx usage relative risk higherdose vioxx usage levesque another study using kaiser permanente data found relative risk lowdose vioxx usage highdose vioxx usage compared current use celecoxib though smaller number statistically significant relative risk compared populations statistically significant graham furthermore recent metastudy randomized trials total participants published jama showed vioxx uniquely increased risk renal kidney disease heart fda issued memo concluding along approved selective nsaids available time ie celecoxib valdecoxib rofecoxib associated increased risk serious adverse cardiovascular events compared placebo also noted available data permit rank ordering drugs regard cardiovascular celebrex generic name celecoxib still available purchase united states regulatory authorities worldwide require warnings cardiovascular risk inhibitors still market example eu regulators required following changes product information andor packaging since withdrawal vioxx come light may negative cardiovascular effects inhibitiors even majority nsaids recent development drugs like vioxx drug companies carried kind well executed trials could establish effects sort trials never carried older trusted nsaids ibuprofen diclofenac others possible exceptions may aspirin naproxen due antiplatelet aggregation properties analyses mcgettigan coxib traditional nsaid trialists cnt collaborators respectively demonstrated risk serious cv events dose dependent effect selective nonselective nsaids possible exception naproxen high therapeutic doses nonselective nsaids eg ibuprofen mgday diclofenac mgday carried similar cv risk compared combined group therapeutic supratherapeutic doses selective nsaids patrono baigent summarizing currently available data review article circulation concluded exception gi toxicity neither efficacy major cardiorenal complications selective nsaids appear influenced level selectivity concluded cv risk associated nsaids dependent dose conclusion reinforced results celecoxib precision trial showed difference cv event rates selective nsaid celecoxib nonselective nsaids ibuprofen due findings approve study merck publicly announced voluntary withdrawal drug market worldwide september addition studies september merck apparently received information new research fda supported previous findings increased risk heart attack among rofecoxib users grassley one fda analyst estimated based upon mathematical model vioxx may caused heart attacks percent probably fatal five years drug market senior fda officials quick note however estimate based solely mathematical model must interpreted november medical journal lancet published metaanalysis available studies safety jüni et al authors concluded owing known cardiovascular risk rofecoxib withdrawn several years earlier lancet published editorial condemned merck fda continued availability rofecoxib merck responded issuing rebuttal jüni et al metaanalysis noted jüni omitted several studies showed increased cardiovascular merck spent million retain john martin jr former us district judge southern district new york colleagues debevoise plimpton llp investigate vioxx study results communications conducted merck report merck called martin report published february report found mercks senior management acted good faith confusion clinical safety vioxx due sales teams overzealous behavior report filed gave timeline events surrounding vioxx stated merck intended operate honestly throughout process mistakes made regarding mishandling clinical trial results withholding information described result oversight malicious behavior report conclude mercks marketing team exaggerated safety vioxx replaced truthful information sales merck satisfied findings report commissioned promised consider recommendations report criticised press selfserving merck insisted report independent merck effect findings conclusions merck hoped report would improve public perception advisory panels us canada encouraged return rofecoxib market stating rofecoxibs benefits outweighed risks patients fda advisory panel voted allow drug return market despite found increase heart risk vote canada canadian panel noted cardiovascular risks rofecoxib seemed worse panel stated study needed nsaids fully understand risk profiles notwithstanding recommendations merck returned rofecoxib following fda advisory committee fda issued memo concluding data large longterm controlled clinical trials clearly demonstrate selective agents including rofecoxib greater risk serious cardiovascular events nonselective fda reinforced conclusion stating available data support dose duration dependent class effect increased risk serious adverse cardiovascular events selective nonselective march cases class actions filed adverse cardiovascular events associated rofecoxib adequacy mercks warnings first wrongful death trial rogers v merck scheduled alabama spring postponed merck argued plaintiff falsified evidence rofecoxib august jury texas voted hold merck liable death robert ernst man allegedly died rofecoxibinduced heart attack merck argued death due cardiac arrhythmia shown associated rofecoxib use jury awarded carol ernst widow robert ernst million damages award capped million punitive damages limits texas merck appealed verdict overturned november merck second case humeston v merck personal injury case atlantic city new jersey plaintiff experienced mild myocardial infarction claimed rofecoxib responsible taken two months merck argued evidence rofecoxib cause humestons injury scientific evidence linking rofecoxib cardiac events short durations use jury ruled merck adequately warned doctors patients drugs first federal trial rofecoxib plunkett v merck began november houston trial ended december judge eldon e fallon us district court declared mistrial hung jury eight one majority favoring defense upon retrial february new orleans vioxx multidistrict litigation mdl based jury found merck liable even though plaintiffs nejm editor testify objections vigor january new jersey state court dismissed case brought edgar lee boyd blamed vioxx gastrointestinal bleeding experienced taking drug judge said boyd failed prove drug caused stomach pain internal bleeding january garza v merck began trial rio grande city texas plaintiff smoker heart disease fatal heart attack three weeks finishing oneweek sample rofecoxib april jury awarded plaintiff million compensatory million punitive texas courts appeals san antonio later ruled garzas fatal heart attack probably resulted preexisting health conditions unrelated taking vioxx thus reversing million jury april jury held merck liable heart attack john mcdarby awarded mcdarby million compensatory damages based mercks failure properly warn vioxx safety risks hearing april jury also awarded mr mcdarby additional million punitive damages jury found merck liable heart attack thomas cona second plaintiff trial liable fraud sale drug cona march australian classaction lawsuit merck ruled vioxx doubled risk heart attacks merck breached trade practices act selling drug unfit november merck announced agreed mass tort settlement billion merck lawyers individual lawsuits tryeverycase strategy opposed class action lawsuit percent plaintiffs sign settlement lawyers case disputed million awarded legal ultimately judge determined fees would awarded plaintiffs judge eldon e fallon united states district court eastern district louisiana additionally ordered plaintiff lawyers cap fees settlement dispute lawyer fees caused scholars observers consider tort reform throughout country articles subject include vioxx litigation critical look trial tactics tort system roles lawyers mass tort years tort reform texas bring fewer suits lower november merck announced civil settlement us attorneys office district massachusetts individually us states district columbia resolve civil claims relating terms settlement merck agreed pay twothirds previously recorded million reserve charge exchange release civil liability litigation seven additional states remains outstanding separate criminal proceedings merck pleaded guilty federal misdemeanor charge relating marketing drug across state lines incurring fine november massachusettsbased tremeau pharmaceuticals announced plan return rofecoxib market treatment hemophilic arthropathy ha tremeau announced fda granted orphan designation rofecoxib treatment ha received fda feedback development ha degenerative joint disease caused recurrent intraarticular bleeding largest cause morbidity patients hemophilia currently approved treatment options united states traditional nsaids avoided population due effects platelet aggregation risk gastrointestinal high potency opioids current standard care treating march tremeau announced hired chief development officer former merck employee product development team leader also responsible executive oversight numerous clinical trials inhibitor vioxx rofecoxib tremeau also announced upcoming clinical trial rofecoxib seeking february californiabased briori biotech announced issued patent covering topical formulations rofecoxib httpsenwikipediaorgwikirofecoxib